CD68-positive tumor-associated macrophages predict unfavorable treatment outcomes in classical Hodgkin lymphoma in correlation with interim fluorodeoxyglucose-positron emission tomography assessment

Leukemia and Lymphoma

Volumn 56, Issue 2, 2015, Pages 332-341

  Touati, Mohamed ^a   Delage Corre, Manuela ^a   Monteil, Jacques ^a   Abraham, Julie ^a   Moreau, Stéphane ^a   Remenieras, Liliane ^a   Gourin, Marie Pierre ^a   Dmytruk, Nataliya ^a   Olivrie, Agnès ^a   Turlure, Pascal ^a   Girault, Stéphane ^a   Labrousse, François ^a   Preux, Pierre Marie ^b   Jaccard, Arnaud ^a   Bordessoule, Dominique ^a  

^a DUPUYTREN UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

Author keywords

CD68; Hodgkin lymphoma; Interim FDG PET; Prognosis

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CD68 ANTIGEN; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE; IFOSFAMIDE; MITOGUAZONE; NAVELBINE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE; VINCRISTINE SULFATE; CD68 ANTIGEN, HUMAN; DIFFERENTIATION ANTIGEN; FLUORODEOXYGLUCOSE F 18; LEUKOCYTE ANTIGEN;

ADOLESCENT; ADULT; AGED; ANALYTICAL RESEARCH; ANTIGEN EXPRESSION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLASSICAL HODGKIN LYMPHOMA; DESCRIPTIVE RESEARCH; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PET-CT SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SALVAGE THERAPY; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE; BIOSYNTHESIS; CHEMORADIOTHERAPY; DISEASE FREE SURVIVAL; FOLLOW UP; HODGKIN DISEASE; KAPLAN MEIER METHOD; MACROPHAGE; METABOLISM; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; CHEMORADIOTHERAPY; DISEASE-FREE SURVIVAL; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HODGKIN DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MACROPHAGES; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84923918362     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2014.917636     Document Type: Article

References (46)

1. Ansell SM. Hodgkin lymphoma: 2012 update on diagnosis, riskstratifi cation, and management. Am J Hematol 2012; 87: 1096-1103
2. Sj ö berg J, Halthur C, Kristinsson SY, et al. Progress in Hodgkin lymphoma: a population-based study on patients diagnosed in Sweden from 1973-2009. Blood 2012; 119: 990-996
3. I nstitut National du Cancer (France). Situation du cancer en France en 2011. pp 97-99. Available from: www.e-cancer.fr/expertisespublications-de-l-inca/rapports-et-expertises/sante-publique
4. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998; 339: 1506-1514
5. Steidl C, Lee T, Shah SP, et al. Tumor-associated macrophages and survival in classic Hodgkin' s lymphoma. N Engl J Med 2010; 362: 875-885
6. S teidl C, Farinha P, Gascoyn R D. M acrophages predict treatment outcome in Hodgkin' s lymphoma. Haematologica 2011; 96: 186-189
7. Lau SK, Chu PG, Weiss LM. CD163 a specifi c marker of macrophages in paraffi n-embedded tissue samples. Am J Clin Pathol 2004; 122: 794-801
8. Tzankov A, Matter MS, Dirnhofer S. Refi ned prognostic role of CD68-positive tumor macrophages in the context of the cellular micromilieu of classical Hodgkin lymphoma. Pathobiology 2010; 77: 301-308
9. Jakovic LR, Mihaljevic BS, Perunicic Jovanovic MD, et al. The prognostic relevance of tumor associated macrophages in advanced stage classical Hodgkin lymphoma. Leuk Lymphoma 2011; 52: 1913-1919
10. K amper P, Bendix K, Hamilton-Dutoit S, et al. T umor-infi ltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in classical Hodgkin's lymphoma. Haematologica 2011; 96: 269-76
11. Yoon DH, Koh YW, Kang HJ, et al. CD68 and CD163 as prognostic factors for Korean patients with Hodgkin lymphoma. Eur J Haematol 2012; 88: 292-305
12. Z aki M A, Wada N, Ikeda J, et al. P rognostic implication of types of tumor-associated macrophages in Hodgkin lymphoma. Virchows Arch 2011; 459: 361-366
13. Tan KL, Scott DW, Hong F, et al. Tumor-associated macrophages predict inferior outcomes in classical Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial. Blood 2012; 120: 3280-3287
14. G reaves P, Clear A, Coutinho R, et al. E xpression of FOXP3, CD68, and CD20 at diagnosis in the microenvironment of classical Hodgkin lymphoma is predictive of outcome. J Clin Oncol 2013; 31: 256-262
15. E, Ribrag V, et al. Macrophage, mast cell and T lymphocyte infi ltrations are independent predictive biomarkers of primary refractoriness or early relapse in classical Hodgkin lymphoma. Leuk Lymphoma 2013; 54: 41-45
16. Casulo C, Arcila M, Bohn OL, et al. Tumor associated macrophages in relapsed and refractory Hodgkin lymphoma. Leuk Res 2013; 37: 1178-1173
17. Azambuja D, Natkuman Y, Biasoli I, et al. Lack of association of tumor-associated macrophages with clinical outcome in patients with classical Hodgkin' s lymphoma. Ann Oncol 2012; 23: 736-742
18. Sanchez-Espiridion B, Martin-Moreno AM, Montalban C, et al. Immunohistochemical markers for tumor associated macrophages and survival in advanced classical Hodgkin lymphoma. Haematologica 2012; 97: 1080-1084
19. Harris JA, Jain S, Ren Q, et al. CD163 versus CD68 in tumor associated macrophages of classical Hodgkin lymphoma. Diagn Pathol 2012; 7: 12
20. C onnors J M. P ositron emission tomography in the management of Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2011: 317-322
21. H utchings M, Mikhaeel N G, Fields P A, et al. P rognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol 2005; 16: 1160-1168
22. Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006; 107: 52-59
23. G allamini A, Hutchings M, Rigacci L, et al. E arly interim 2-[18F]fl uoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to International Prognostic Score in advancedstage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 2007; 25: 3746-3752
24. B arnes J A, LaCasce A S, Zukotynski K, et al. E nd-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin' s lymphoma. Ann Oncol 2011; 22: 910-915
25. M eignan M, Barrington S, Itti E, et al. R eport on the 4th International Workshop on Positron Emission Tomography in Lymphoma held in Menton, France, 3-5 October 2012. Leuk Lymphoma 2014; 55: 31-37
26. Ferme C, Cosset JM, Fervers B, et al.; French National Federation of Cancer (FNCLCC). Hodgkin' s disease. Br J Cancer 2001; 84(Suppl. 2): 55-60
27. Engert A, Dreyling M. Hodgkin's lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. On behalf of the ESMO Guidelines Working Group. Ann Oncol 2008; 19(Suppl. 2): ii65-ii66
28. Brice P. Managing relapsed and refractory Hodgkin lymphoma. Br J Haematol 2008; 141: 3-13
29. Lister TA, Crowther D, Sutcliff e SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989; 7: 1630-1636
30. Cheson BD, Horning SJ, Coiffi er B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999; 17: 1244-1253
31. Cheson BD, Pfi stner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579-586
32. Jaff e E S. The 2008 WHO classifi cation of lymphomas: implications for clinical practice and translational research. Hematology Am Soc Hematol Educ Program 2009: 523-531
33. Monteil J, Mahmoudi N, Leobon S, et al. Chemotherapy response evaluation in metastatic colorectal cancer with FDG PET/CT and CT scans. Anticancer Res 2009; 29: 2563-2568
34. Van Den Neste E, Casasnovas O, Andr é M, et al. Classical Hodgkin's lymphoma: the Lymphoma Study Association guidelines for relapsed and refractory adult patients eligible for transplant. Haematologica 2013; 98: 1185-1195
35. Hutchings M. How does PET/CT help in selecting therapy for patients with Hodgkin lymphoma? Hematology Am Soc Hematol Educ Program 2012: 322-327
36. Meignan M, Gallamini A, Haioun C. Report on the fi rst international workshop on interim-PET scan in lymphoma. Leuk Lymphoma 2009; 50: 1257-1260
37. Meignan M, Gallamini A, Itti E, et al. Report on the Th ird International Workshop on Interim Positron Emission Tomography in Lymphoma held in Menton, France, 26-27 September 2011 and Menton 2011 consensus. Leuk Lymphoma 2012; 53: 1876-1881
38. G allamini A, Kostakoglu L. I nterim FDG-PET in Hodgkin lymphoma: a compass for a safe navigation in clinical trials? Blood 2012; 120: 4913-4920
39. B iggi A, Gallamini A, Chauvie S, et al. I nternational validation study for Interim PET in ABVD-treated, advanced-stage Hodgkin lymphoma: interpretation criteria and concordance rate among reviewers. J Nucl Med 2013; 54: 683-690
40. Gascoyne RD, Scott DW, Steidl C. Molecular pathology of Hodgkin's lymphoma: prognostic implications. Hematol Educ 2012; 6: 165-174
41. Steidl C, Connors JM, Gascoyne RD. Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment. J Clin Oncol 2011; 29: 1812-1826
42. Diehl V. Are macrophages the bad gays in Hodgkin lymphoma? Nat Rev Clin Oncol 2010; 7: 301-302
43. Blum KA. Upcoming diagnosis and therapeutic developments in classical Hodgkin's lymphoma. Hematology Am Soc Hematol Educ Program 2010: 93-100
44. Borchmann P, Engert A. Clinical advances in Hodgkin lymphoma. The past: what we have learned in the last decade. Hematology Am Soc Hematol Educ Program 2010: 101-107
45. G allamini A, Barrington S F, Biggi A, et al. The predictive role of interim positron emission tomography on Hodgkin lymphoma treatment outcome is confi rmed using the 5-point scale interpretation criteria. Haematologica 2014 Mar 21. [Epub ahead of print]
46. Oki Y, Chuang H, Chasen B, et al. The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma. Br J Haematol 2014; 165: 112-116.